Breaking News
Get 40% Off 0
Is NVDA a 🟢 buy or 🔴 sell? Unlock Now

Diabetes drugs like Ozempic boost glucose monitor sales

Published Nov 20, 2023 07:14
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.
 
ABT
-0.44%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
DXCM
+0.71%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Amid rising concerns that advanced diabetic treatments could reduce the need for blood glucose monitoring devices, recent financial reports indicate a contrasting trend. Companies such as Abbott Laboratories (NYSE:ABT) and DexCom are experiencing a surge in demand for continuous glucose monitors (CGMs), driven by the side effects of diabetes medications that can induce hypoglycemia, thus requiring more vigilant blood sugar tracking.

The third-quarter financials have been particularly telling of this unexpected boon. Abbott Laboratories reported a 30% increase in sales for its FreeStyle Libre system, reaching $1.4 billion. Similarly, DexCom witnessed a 27% revenue rise to $975 million. These figures underscore a growing reliance on CGMs by patients using diabetic treatments, including Ozempic, Eli Lilly’s Mounjaro, Wegovy, Rybelsus, and Zepbound. While these medications are lauded for their effectiveness in managing diabetes and obesity and reducing cardiovascular disease risks, they also necessitate closer glucose monitoring due to the risk of hypoglycemia they pose.

Insurance claims data analyses have corroborated this trend, revealing that patients on intensive insulin regimens have doubled their use of monitoring devices. Even more striking is the quadrupled usage among non-insulin-dependent users. This increased dependence on CGMs is anticipated to persist and may even contribute positively to the share prices of companies like Abbott and DexCom.

As these firms capitalize on the synergy between drug therapy and device monitoring, industry experts predict a redefinition of diabetes care dynamics. The enhanced use of CGMs in conjunction with diabetic medications appears to be shaping a new landscape in diabetes management where device monitoring plays an integral role in ensuring patient safety and efficacy of treatment protocols.

InvestingPro Insights

As the landscape of diabetes management evolves, Abbott Laboratories and DexCom are making significant strides in their respective markets. According to InvestingPro data, Abbott Laboratories boasts a robust market cap of 172.82B USD and a P/E ratio of 33.69 as of Q3 2023. The company has also witnessed a revenue growth of -11.26% over the last twelve months as of Q3 2023.

InvestingPro Tips highlight that Abbott Laboratories yields a high return on invested capital and has raised its dividend for 10 consecutive years. This is a testament to the company's financial stability and consistent growth.

On the other hand, DexCom, with a market cap of 40.56B USD and a P/E ratio of 107.95 as of Q3 2023, has seen a remarkable revenue growth of 21.85% over the last twelve months as of Q3 2023. InvestingPro Tips indicate that DexCom's revenue growth has been accelerating, and that 19 analysts have revised their earnings upwards for the upcoming period.

These insights underscore the potential of both companies in the CGM market. For more detailed analysis and tips, consider subscribing to InvestingPro, which is now on a special Black Friday sale with a discount of up to 55%. With over 30 additional tips available for each company, InvestingPro offers invaluable insights for savvy investors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Diabetes drugs like Ozempic boost glucose monitor sales
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email